Regeneron Pharmaceuticals, Inc.
REGN
$828.50
-$5.54-0.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.35% | 16.54% | 0.99% | -1.40% | 1.43% |
| Total Other Revenue | 5.11% | 109.04% | 33.00% | 73.56% | 75.98% |
| Total Revenue | 16.73% | 19.04% | 2.51% | 0.90% | 3.62% |
| Cost of Revenue | 13.13% | 23.51% | 11.79% | 13.28% | 16.17% |
| Gross Profit | 20.82% | 12.57% | -7.62% | -10.23% | -7.67% |
| SG&A Expenses | 4.40% | 2.32% | -2.17% | -7.92% | -16.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.99% | 17.98% | 7.80% | 6.76% | 6.03% |
| Operating Income | 30.38% | 23.31% | -11.86% | -10.76% | -1.68% |
| Income Before Tax | 0.60% | -8.15% | 8.93% | 18.10% | -6.72% |
| Income Tax Expenses | 81.67% | 8.00% | 392.82% | 99.02% | -35.09% |
| Earnings from Continuing Operations | -6.81% | -10.08% | -7.97% | 8.91% | -2.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.81% | -10.08% | -7.97% | 8.91% | -2.84% |
| EBIT | 30.38% | 23.31% | -11.86% | -10.76% | -1.68% |
| EBITDA | 26.10% | 18.76% | -8.93% | -8.70% | -0.34% |
| EPS Basic | -4.72% | -7.74% | -3.76% | 13.64% | -0.07% |
| Normalized Basic EPS | 27.36% | 19.84% | 77.68% | -6.94% | 3.23% |
| EPS Diluted | -4.53% | -7.15% | -2.64% | 18.02% | 3.22% |
| Normalized Diluted EPS | 27.63% | 20.61% | 79.88% | -3.32% | 6.64% |
| Average Basic Shares Outstanding | -2.19% | -2.53% | -4.37% | -4.16% | -2.78% |
| Average Diluted Shares Outstanding | -2.39% | -3.15% | -5.54% | -7.75% | -5.89% |
| Dividend Per Share | 6.82% | 6.82% | -- | -- | -- |
| Payout Ratio | 0.12% | 0.16% | -- | -- | -- |